[{"orgOrder":0,"company":"Future Pharmaceutical Industries","sponsor":"Future Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Levofloxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Future Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Future Pharmaceutical Industries \/ Future Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"Future Pharmaceutical Industries \/ Future Pharmaceutical Industries"}]

Find Clinical Drug Pipeline Developments & Deals by Future Pharmaceutical Industries

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibiotic

                          Upfront Cash : Inapplicable

                          January 11, 2022

                          Lead Product(s) : Levofloxacin

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Recipient : National Liver Institute, Egypt

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank